Boston Scientific Q3 revenue revs up 1.5% to $5.14 billion
Key points
- Boston Scientific (NYSE:BSX) reported third-quarter 2026 sales of $5.138 billion, up 1.5% year over year, slightly exceeding analysts' expectations.
- Adjusted earnings per share fell to $0.73 from $0.75, missing the $0.75 consensus estimate, while GAAP net income dropped to $582 million.
- The company forecast fourth-quarter sales declines of 1%–3% and full-year adjusted earnings per share of $3.16–$3.18 following operational disruption from a cybersecurity incident.
Boston Scientific (NYSE:BSX) reported third-quarter 2026 revenue of $5.138 billion, up 1.5% year over year, while adjusted earnings per share fell short of analysts' expectations at $0.73.
Revenue narrowly beat the $5.12 billion consensus estimate, but adjusted earnings per share missed the $0.75 forecast, and GAAP net income declined to $582 million from $755 million a year earlier.
Cardiovascular sales rose 1.9% to approximately $3.41 billion, while MedSurg sales increased 0.6% to approximately $1.73 billion, as U.S. sales grew 0.5%, EMEA sales rose 4.4% and Asia-Pacific sales declined 0.6%.
Following the results and weaker outlook, Boston Scientific shares fell more than 3% in trading, according to market reports.
The company forecast fourth-quarter 2026 sales to decline 1%–3% year over year and adjusted earnings per share of $0.77–$0.79, while projecting full-year adjusted earnings per share of $3.16–$3.18.
Frequently asked questions
More from United States
Generac achieves $1.29 billion quarterly sales milestone
Del Monte posts $1.10 billion Q3 revenue amid continued growth
Aon revenue increases 3% to $4.10 billion in third quarter
Otis revenue momentum lifts quarterly sales to $3.91 billion
GE Vernova Q3 revenue rockets 26.8% to $12.64 billion
GE HealthCare revenue climbs 7.2% in Q3 as sales top $5.5B
